The Anti-CD3-Induced Syndrome: A Consequence of Massive In Vivo Cell Activation
- 1 January 1991
- book chapter
- review article
- Published by Springer Science and Business Media LLC in Current Topics in Microbiology and Immunology
- Vol. 174, 121-134
- https://doi.org/10.1007/978-3-642-50998-8_9
Abstract
No abstract availableThis publication has 46 references indexed in Scilit:
- IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATIONTransplantation, 1990
- Hypothermia and hypoglycemia induced by anti‐CD3 monoclonal antibody in mice: Role of tumor necrosis factorEuropean Journal of Immunology, 1990
- Systemic Reaction to the Anti–T-Cell Monoclonal Antibody OKT3 in Relation to Serum Levels of Tumor Necrosis Factor and Interferon-αThe New England Journal of Medicine, 1989
- Clinical use of OKT3: The role of cytokine release and xenosensitizationJournal of Autoimmunity, 1988
- Detection of Circulating Tumor Necrosis Factor after Endotoxin AdministrationThe New England Journal of Medicine, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneThe New England Journal of Medicine, 1987
- A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadaveric Renal TransplantsThe New England Journal of Medicine, 1985
- Antigenic modulation - a major mechanism of antibody actionImmunology Today, 1984
- EFFECTS OF IN VIVO ADMINISTRATION OF MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN T CELL SUBPOPULATIONS ON THE IMMUNE SYSTEM IN A RHESUS MONKEY MODELTransplantation, 1983
- Use of Monoclonal Antibodies to T-Cell Subsets for Immunologic Monitoring and Treatment in Recipients of Renal AllograftsThe New England Journal of Medicine, 1981